Prof. Chris Mathew, the lead investigator, stated that understanding the role of genes like USP22 can aid in identifying patients requiring more intensive treatment and follow-up.

A groundbreaking study has identified genetic variants associated with breast cancer specifically in Black South African women, marking the first genome-wide association study (GWAS) of breast cancer conducted on the African continent.

RAB27A is part of the RAS oncogene family, while USP22 is linked to poor prognosis in breast cancer, indicating their potential role in the disease's genetic basis.

The institute recommends regular mammograms, self-checks, and healthy lifestyle choices for early detection and treatment of breast cancer.

More genomic knowledge could lead to more precise treatments tailored to specific populations.

If confirmed, these genetic markers may also serve as biomarkers to predict aggressive cancer forms, guiding treatment and monitoring strategies for affected patients.

The research aims to bridge the knowledge gap in cancer susceptibility across different populations in Africa and globally.

Co-lead author Dr. Jean-Tristan Brandenburg noted that the lack of data on African populations complicates accurate disease risk prediction.

The findings could lead to the development of targeted drugs aimed at the newly identified genes, potentially enhancing treatment precision by focusing on harmful cancer cells while protecting healthy tissue.

Further studies are needed to confirm these findings, but USP22 and RAB27A may serve as potential targets for new precision anti-cancer drugs.